Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
It is still too early to determine any definitive federal policies for 2025 (or beyond) that could affect these companies. However, some analysts have speculated that the administration might restrict ...
Tempus AI stock contract value exceeds $1.1B with 70 pharma deals. Diagnostics revenue up 111%, data segment up 31% in 2025 ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I'm back in ...
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. Pfizer plans to invest $1 billion in China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback